[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Research Letter
February 2017

Quality Assessment of 7 Cardiovascular Drugs in 10 Sub-Saharan CountriesThe SEVEN Study

Author Affiliations
  • 1Department of Pharmacy, Saint-Antoine Hospital, East Paris University Hospitals, AP-HP, Paris, France
  • 2Cardiology Department, University Hospital Fann, Dakar, Senegal
  • 3Department of Laboratories, General Agency of Health Equipment and Products, AP-HP, Paris, France
  • 4Faculty of Pharmacy, University of Paris-Sud, UA 401, Chatenay-Malabry, France
  • 5Cardiology Department, Cardiology Institute of Abidjan, Abidjan, Côte d’Ivoire
  • 6Internal Medicine and Cardiology Department, Lamordé National Hospital, Abdou Moumouni University, Niamey, Niger
  • 7Cardiology Department, National Hospital of Sanou Souro of Bobo Dioulasso, Ouagadougou, Burkina Faso
  • 8Department of Cardiology, European Georges Pompidou Hospital, AP-HP, Paris, France
  • 9INSERM U970, Paris, France
  • 10Paris Descartes University, Paris, France

Copyright 2016 American Medical Association. All Rights Reserved.

JAMA Cardiol. 2017;2(2):223-225. doi:10.1001/jamacardio.2016.3851

Substandard and falsified medicines pose a serious threat to patient safety and public health.1 Studies on the quality of drugs have focused mainly on antimicrobial agents, such as antiretroviral therapy (for human immunodeficiency virus) and antimalarial medications.2 Although cardiovascular disease kills millions of Africans,3 to our knowledge, little published research has explored the quality of essential cardiovascular disease medicines to date. We therefore performed a quality assessment of 7 commonly used cardiac drugs (ie, an anticoagulant drug, a statin, and 5 antihypertensive drugs) in 10 countries of sub-Saharan Africa.

First Page Preview View Large
First page PDF preview
First page PDF preview